Need to support HTA Mechanism and contain access to innovation inequalities across Member States
With the participation of 28 distinguished Greek and foreign speakers and more than 240 participants, including health professionals, researchers, academics, policy makers, industry representatives and patients, the largest annual conference on the Evaluation of Health Technologies (HTA) in Greece, organized by Health Daily and BOUSSIAS EVENTS, was concluded successfully. The 9th HTA conference, under the specific title: HTA in a Changing World: Navigating New Challenges and Opportunities”, took place on April 23rd, 2024 in Athens at the DIVANI CARAVEL Ηotel.
With the pressing need for Health Technology Assessment to evolve alongside the accelerating advancements in healthcare technology, the 2024 conference was strategically positioned to delve into the intricacies of these changes, exploring how HTA can effectively navigate the challenges and seize the opportunities that lie ahead.
As of January 2025, the new Joint HTA Regulation will come into full effect, ushering in a new era of standards and expectations. Towards that goal, significant interventions were made by important international and Greek Academics, pharma executives and representatives of institutions, the State and patients who actively participated in the proceedings, collaborating on ideas, and exploring innovative solutions to the most pressing challenges in healthcare.
The conference was held under the auspices of the Panhellenic Pharmaceutical Industry Union (PEF), the Hellenic Market Access Union (ELEMA) and the PhRMA Innovation Forum (PIF).
The Conference
The main theme of the 2024 conference is “HTA in a Changing World: Navigating New Challenges and Opportunities“. The main theme resonates with the pressing need for Health Technology Assessment to evolve alongside the accelerating advancements in healthcare technology. As of January 2025, the new Joint HTA Regulation will come into full effect, ushering in a new era of standards and expectations. The 2024 conference is strategically positioned to delve into the intricacies of these changes, exploring how HTA can effectively navigate the challenges and seize the opportunities that lie ahead.
With the Joint HTA Regulation on the horizon, the conference emphasizes the need for strengthened collaboration among European stakeholders. It serves as a platform for professionals from diverse backgrounds to exchange ideas, share best practices, and foster collaborations that transcend borders. Through collaborative efforts, attendees will explore how European nations can collectively enhance HTA practices, ensuring a harmonized approach to evaluating healthcare technologies.
This conference is a unique opportunity to discuss in a multi-disciplinary environment the opportunities, the challenges and the future of National and European cooperation on HTA for the benefit of patients, healthcare systems and society at large.
Don’t miss your chance to be at the forefront of HTA’s evolution. Join us at the 9th HTA Conference, where innovation, collaboration, and adaptation converge to chart the course for the future of healthcare. Secure your spot now, and together, let’s navigate the new challenges and opportunities that lie ahead in the ever-changing world of HTA.
Speakers
Key Issues
Topics that will be addressed:
- Updates on HTA at a European and local level
- Impact of the New European HTA Regulation on Healthcare Innovation
- The Role of HTA in Greece and future strategy
- Integrating HTA into value-based healthcare models and its implications for improving healthcare outcomes in Greece
- Joint HTA on Medical Devices Looking Ahead
- Evaluating the effectiveness and cost-effectiveness of therapeutic protocols/ Establishing a roadmap for the integration of therapeutic protocols into HTA frameworks
- Strategies for harmonizing therapeutic protocols with evidence-based medicine
- Risk-sharing agreements for gene therapies
- Translating Economic Impact of Innovation to Value for patients
- Issues regarding Pricing and Access to Gene and Advanced Therapy Medicinal Products
- Budget Impact Analysis: Principles of Good Practice and Learnings from EU Experience
- Overview of recent changes to HTA Methodologies that enable full value of ATMPs to be captured in HTA
- The use of federated data in evidence generation
- Advancing the use of real world evidence in health technology assessment: insights from a multi-stakeholder workshop
- The best practices and actions for stakeholders to improve the quality and transparency of RWE studies
Who should Attend?
- Government representatives
- Pharmaceutical industry executives (Market Access, Government Affairs, Health Economics)
- Public & Private Health services providers
- Health economists
- Health Policy Experts
- Healthcare Professionals
- Academics
- Physicians
- Patient advocates & patient group representatives
- Journalists
Testimonials
Sponsors
Econcare, a contract research organization (CRO) and consulting firm in life sciences, specializes in Clinical Trials, Biostatistics and epidemiology, Medical Writing, Health Technology Assessment (HTA), Health Economics & Outcomes Research (HEOR), Market Access, Pricing, and Regulatory Affairs. With an experienced team, Econcare delivers high-quality projects across all major therapeutic areas.
ELPEN has been active for 59 years in the production of branded Greek medicines. With more than 1,450 employees at group level, the company invests more than 10% of its annual turnover in research projects. In 1996 ELPEN founded its Experimental, Research & Training Center. ELPEN is highly recognized in international markets with exports of more than 30 medical products in 90 countries worldwide.
Health Through Evidence (HTE) is a leading HEOR and market access consultancy with a reputation for high-quality services, technical expertise, field experience, and evidence-based solutions. HTE is built on a passion for science and research, dedicated to contributing to the translation of new knowledge into clinical practice. Our services span HEOR, health technology assessments, market access, pricing& regulatory affairs, real-world evidence generation, medical writing, and data analytics.
Inspired by the synthesis of key-words Health, IT and Think, HealThink was founded to provide high-class market access, health technology assessment (HTA) and R&D services. Based on a long experience on Medical/Scientific Coordination of HTA, digital health and RWD projects, a multidisciplinary team of professionals with diverse scientific background has been created, able to respond to highly demanding projects.
IQVIA (NYSE:IQV) is a leading global provider of information, innovative technology solutions and contract research services dedicated to using analytics and science to help healthcare stakeholders find better solutions for their patients. Solutions are powered by the IQVIA CORE™, which combines big data, advanced technology, analytics and extensive industry knowledge. Formed through the merger of IMS Health and Quintiles, IQVIA has approximately 70,000 employees worldwide. Learn more at iqvia.com.
Under the Auspices
Media Partner
Media Sponsors
Audiovisual Sponsor
CONEQ provides technical equipment and services to any kind of event. With our Simultaneous Interpretation Systems, Conference Systems, AudioVisual Equipment we support events and provide the best service to our customers. Our professionalism, our high quality of service and state of the art equipment offered to over 600 large and of great significance conferences during the last 5 years have certainly contributed to our constant uptrend. Call us at (+30) 211 2163453. or email us at [email protected]
